Show Menu

A fully integrated developer and manufacturer of ovine polyclonal therapeutics, targeting infectious disease and acute toxic events

News: Latest Posts

Contract Awarded for Manufacture of a Ricin Antitoxin

MicroPharm Limited is pleased to announce the award of a contract offered by the Defence Science and Technology Laboratory (Dstl) on behalf of the Ministry of Defence (MOD) to manufacture a ricin antitoxin. 

Read the full story

Posted on: Tuesday, 23rd August 2016

MicroPharm-PHE Ebola Partnership in the Spotlight

MicroPharm is pleased to announce that its promising ovine polyclonal antibody against Ebola, developed in collaboration with Public Health England (PHE) and the University of Oxford, has been in the spotlight as an example of good practice in knowledge exchange and commercialisation.

Read the full story

Posted on: Friday, 16th October 2015

Investment in Research & Development

MicroPharm is pleased to announce that Flynn Pharma (Holdings) Ltd has acquired a majority shareholding in the Company.

Read the full story

Posted on: Friday, 14th August 2015

Ovine antibodies to treat Ebola Virus Disease

MicroPharm Limited is pleased to announce that, following promising in vitro results, its ovine polyclonal antibody against Ebola has advanced to the in vivo evaluation stage of a Wellcome Trust-funded project for rapid down-selection of experimental Ebola therapies. These antibodies are being developed in collaboration with Public Health England (PHE) and the University of Oxford.

Read the full story

Posted on: Wednesday, 14th January 2015

Ovine antibodies to treat Ebola

MicroPharm Limited is pleased to announce that it is developing ovine polyclonal antibodies against Ebola  in collaboration with Public Health England (PHE) and the University of Oxford, and our candidate is one of twenty going through the first round of evaluation by PHE for efficacy against the  Ebola virus.

Read the full story

Posted on: Friday, 19th December 2014